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LETTER TO THE EDITOR
Cetuximab-induced esophageal ulcer: the first report in
literature
C
etuximab, a monoclonal antibody to the extra-
cellular domain of epidermal growth factor
receptor (EGFR), is indicated for the treatment
of metastatic colorectal cancers and headneck cancers.
Cetuximab is generally well tolerated but some side
effects, such as skin rash, malaise, vomiting, diarrhea,
hypomagnesemia, and hypersensitivity reactions, have
been reported (1, 2). Esophageal ulcer in patients
receiving cetuximab treatment has not been described
previously. We herein report a 59-year-old man diagnosed
with metastatic rectal cancer with esophageal ulcers
associated with cetuximab after five cycles of treatment.
To the best of our knowledge, this is the first report that
shows cetuximab may induce esophageal ulcers, which
may be precursor lesions to a gastrointestinal tract
perforation.
A 59-year-old man with constipation and pelvic pain
was admitted to the gastroenterology outpatient depart-
ment. A flexible rectoscopic examination revealed a rigid
and painful mass encircling the lumen of the rectum.
Biopsy specimen of the rectal mass confirmed a well-
differentiated adenocarcinoma of the rectum. Surgery
was planned, but the patient was refused the procedure
and was kept under follow-up. Three months later, the
patient was referred to the emergency department with
acute abdominal pain, vomiting, impaired defecation,
and fever. Due to intestinal obstruction, laparotomy was
performed for surgical resection, although pre-operative
computed tomographic (CT) scans showed evidence of
possible invasion to the urinary tract and perirectal
tissue. At surgery, the tumor could barely be mobilized
due to direct invasion into the surrounding tissues,
and the operation ended in a simple sigmoid colostomy
to relieve his condition. In order to treat rectal cancer,
infusional 5-FU and oxaliplatin-based chemoradiother-
apy was administered. After the chemoradiotherapy,
CT scan showed partial regression on the rectum and
perirectal tissues, but a metastatic mass was observed
on the left surrenal. Positron emission tomography
(PET)-CT scan confirmed this surrenal mass and rectal
involvement with a moderate Fluorodeoxyglucose (FDG)
accumulation. Because v-Ki-ras2 Kirsten rat sarcoma
viral oncogene (KRAS) sequencing of a tumor biopsy
sample showed wild-type, he was started on second-line
chemotherapy with cetuximab 500 mg/m2 and irinotecan
180 mg/m2 every 2 weeks. After three cycles of cetuximab
and irinotecan, the patient had odynophagia and endo-
scopy was planned but the patient refused the procedure.
Chemotherapy was continued with the same protocol
because the patient deteriorated after five cycles of
treatment. Patient refused third-line chemotherapy set-
ting and was followed up with the best supportive
care. Two weeks later, the patient was admitted to our
outpatient department with hematemesis and melena.
The patient’s hemoglobin level was revealed to be 6.8 g/dl.
An endoscopic examination showed a large, deep,
white exuding ulcer in the lower third of the esophagus.
There was a visible vessel in the middle of the ulcer.
Argon plasma coagulation stopped the bleeding. Proton
pump inhibitor was also started and biopsies were taken
from the edge of the ulcer. Pathological evaluation of
the ulcer showed acute inflammation. Cytomegalovirus
(CMV) IgG and IgM was also negative. There was no
prior history of use of any medications known to induce
esophageal ulcer. Based on these laboratory and clinical
findings, we assumed that esophageal ulcer was related to
cetuximab treatment.
Gastrointestinal (GI) ulcers have been described pre-
viously in 10 of 755 patients (1.3%) with colorectal cancer
who were treated with chemotherapy and bevacizumab
(3). Mechanisms underlying GI perforation and ulcera-
tion in patients treated with bevacizumab are unknown;
however, evidence supports that vascular endothelial
growth factor (VEGF) plays a major role in this process.
Tarnawski (4) described cellular and molecular mechan-
isms of gastrointestinal ulcer healing; this process is
controlled by cytokines and growth factors, including
VEGF. Esophageal ulcer in patients receiving cetuximab
treatment has not been described previously, and may be
the precursor lesion to a gastrointestinal tract perfora-
tion. We herein report a 59-year-old man diagnosed as
metastatic rectal cancer with esophageal ulcers associated
with cetuximab after five cycles of treatment. Cetuximab
blocks activation of receptor-related kinases, resulting in
inhibition of cell growth, apoptosis, decreased VEGF and
matrix metalloproteinases production (5). Reduced levels
of VEGF and matrix metalloproteinases may induce
esophageal ulcer in cetuximab setting patients. It is
possible that cetuximab, in addition to chemotherapy,
causes esophageal mucosal inflammation resulting in
mucosal breaks and ulceration. Further studies are
needed to explain the exact mechanism of esophageal
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ulcer formation related to cetuximab. This report shows
the importance of elucidating upper GI symptomatology
in patients receiving cetuximab and the necessity of
performing early endoscopy to rule out an esophageal
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